Legend Biotech (NASDAQ:LEGN – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at Royal Bank of Canada in a research note issued on Thursday, Benzinga reports. They currently have a $85.00 target price on the stock. Royal Bank of Canada’s target price would indicate a potential upside of 34.39% from the stock’s previous close. A number of other equities research analysts have also recently commented on the company. Scotiabank initiated coverage on Legend Biotech in a research note on Tuesday, December 19th. They issued a “sector perform” rating and a $65.00 price target for the company. Barclays increased their price objective on Legend Biotech from $93.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, January 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $87.00 price objective on shares of Legend Biotech in a report on Friday, December 22nd. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $82.61. Read Our Latest Research Report on Legend Biotech Legend Biotech Stock Down 1.5 % Institutional Trading of Legend Biotech Hedge funds and other institutional investors have recently bought and sold shares of the stock. BluePath Capital Management LLC acquired a new stake in Legend Biotech during the third quarter worth about $32,000. Coppell Advisory Solutions LLC acquired a new stake in Legend Biotech in the second quarter valued at approximately $41,000. American International Group Inc. acquired a new stake in Legend Biotech in the second quarter valued at approximately $33,000. Lazard Asset Management LLC acquired a new stake in Legend Biotech in the fourth quarter valued at approximately $33,000. Finally, Quarry LP acquired a new stake in Legend Biotech in the fourth quarter valued at approximately $45,000. 49.61% of the stock is owned by institutional investors and hedge funds. About Legend Biotech Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). See Also Five stocks we like better than Legend Biotech The 3 Best Blue-Chip Stocks to Buy Now What is a Microcap Stock? Everything You Need to Know The Most Important Warren Buffett Stock for Investors: His Own How to Invest in Casino Stocks: Pros and Cons and More Unveiling The Power Of VWAP: A Key Indicator For Traders How to Invest in Cannabis in 8 Easy Steps Receive News & Ratings for Legend Biotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Legend Biotech and related companies with MarketBeat.com’s FREE daily email newsletter.
This content was originally published here.
